Takaisin Tulosta

Lääkehoitojen vaikutus katkokävelyn oireisiin

Lisätietoa aiheesta
Pekka Romsi
18.2.2021

Kirjallisuutta

  1. Bagger JP, Helligsoe P, Randsbaek F ym. Effect of verapamil in intermittent claudication A randomized, double-blind, placebo-controlled, cross-over study after individual dose-response assessment. Circulation 1997;95:411-4 «PMID: 9008458»PubMed
  2. Gargiulo G, Giugliano G, Brevetti L ym. Use of statins in lower extremity artery disease: a review. BMC Surg 2012;12 Suppl 1:S15 «PMID: 23173874»PubMed
  3. McDermott MM, Guralnik JM, Greenland P ym. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation 2003;107:757-61 «PMID: 12578881»PubMed
  4. Robertson L, Andras A. Prostanoids for intermittent claudication. Cochrane Database Syst Rev 2013;:CD000986 «PMID: 23633305»PubMed
  5. Momsen AH, Jensen MB, Norager CB ym. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg 2009;38:463-74 «PMID: 19586783»PubMed
  6. Stevens JW, Simpson E, Harnan S ym. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012;99:1630-8 «PMID: 23034699»PubMed
  7. Dolmatch BL, Rholl KS, Moskowitz LB ym. Blue toe syndrome: treatment with percutaneous atherectomy. Radiology 1989;173:799-804 «PMID: 2813788»PubMed
  8. Aung PP, Maxwell HG, Jepson RG ym. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;:CD000123 «PMID: 17943736»PubMed
  9. Shahin Y, Barnes R, Barakat H ym. Meta-analysis of angiotensin converting enzyme inhibitors effect on walking ability and ankle brachial pressure index in patients with intermittent claudication. Atherosclerosis 2013;231:283-90 «PMID: 24267241»PubMed
  10. Vlachopoulos C, Terentes-Printzios D, Aboyans V ym. Angiotensin converting enzyme inhibitors and walking distance: Have we walked the whole distance? Atherosclerosis 2016;252:199-200 «PMID: 27543007»PubMed
  11. Espinola-Klein C, Weisser G, Jagodzinski A ym. ß-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011;58:148-54 «PMID: 21646599»PubMed
  12. Bedenis R, Stewart M, Cleanthis M ym. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014;:CD003748 «PMID: 25358850»PubMed
  13. Hiatt WR, Money SR, Brass EP. Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). J Vasc Surg 2008;47:330-336 «PMID: 18155871»PubMed
  14. De Backer TL, Vander Stichele R, Lehert P ym. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008;:CD001368 «PMID: 18425872»PubMed
  15. Boccalon H, Lehert P, Mosnier M. [Effect of naftidrofuryl on physiological walking distance in patients with intermittent claudication]. Ann Cardiol Angeiol (Paris) 2001;50:175-82 «PMID: 12555510»PubMed
  16. Nicolaï SP, Kruidenier LM, Bendermacher BL ym. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2013;:CD006888 «PMID: 23744597»PubMed
  17. Salhiyyah K, Senanayake E, Abdel-Hadi M ym. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012;1:CD005262 «PMID: 22258961»PubMed
  18. Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000;:CD000987 «PMID: 10796571»PubMed
  19. Pittler MH, Ernst E. Complementary therapies for peripheral arterial disease: systematic review. Atherosclerosis 2005;181:1-7 «PMID: 15939048»PubMed
  20. Sommerfield T, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2007;:CD003833 «PMID: 17943801»PubMed
  21. Campbell A, Price J, Hiatt WR. Omega-3 fatty acids for intermittent claudication. Cochrane Database Syst Rev 2013;:CD003833 «PMID: 23824785»PubMed